Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Sean M. Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama

doi:10.18632/oncotarget.123

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Sean M. Post, Vinod Pant, Hussein Abbas and Alfonso Quintás-Cardama _

PDF | How to cite

Oncotarget. 2010; 1:168-174. https://doi.org/10.18632/oncotarget.123

Metrics: PDF 2490 views | ?

Abstract

Received: July 7, 2010, Accepted: July 26, 2010, Published: July 27, 2010

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 123

Publication Alerts

Reviews:

Prognostic impact of the MDM2SNP309 Allele in Leukemia and Lymphoma

Abstract